The eIF-2-Alpha Kinase GCN2 pipeline drugs market research report outlays comprehensive information on the eIF-2-Alpha Kinase GCN2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the eIF-2-Alpha Kinase GCN2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology which include the indications Solid Tumor, and Renal Cell Carcinoma. It also reviews key players involved in eIF-2-Alpha Kinase GCN2 targeted therapeutics development with respective active and dormant or discontinued products.
The eIF-2-Alpha Kinase GCN2 pipeline targets constitutes close to 12 molecules. Out of which, approximately 12 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 2, 2, 6, and 2 respectively.
eIF-2-Alpha Kinase GCN2 overview
Eukaryotic Translation Initiation Factor 2 Alpha Kinase 4 is an enzyme that in humans is encoded by a gene EIF2AK4. It is a member of eIF2-alpha kinase family and provides instructions for making a protein involved in cellular processes related to protein synthesis. The protein produced from this gene is a kinase, a type of enzyme that adds phosphate groups to other proteins. The eIF2-alpha kinases play a role in the regulation of translation initiation, a critical step in the synthesis of proteins. The phosphorylation of eIF2-alpha is a regulatory mechanism that can control the overall rate of protein synthesis in response to various cellular stresses, including nutrient deprivation, endoplasmic reticulum stress, and viral infection. The EIF2AK4 gene and its protein product are part of the broader cellular machinery that helps cells adapt to changing conditions and maintain protein homeostasis. Dysregulation of eIF2-alpha kinases has been implicated in various diseases, including cancer and neurodegenerative disorders.
For a complete picture of eIF-2-Alpha Kinase GCN2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
